GenSci

CN

1
/
/
R&D Updates

Key R&D Progress

Study May Proceed for Gentulizumab
Study
On December 18, 2020, Beijing time, GenSci’s Gentulizumab R&D project was approved by the US FDA for clinical trials, which means that this innovative therapy will soon proceed to clinical research in the United States. This is another milestone achievement following the approval of the project by the National Medical Products Administration (NMPA) for clinical trials in September of the same year.

The Gentulizumab injection is developed for advanced malignant solid tumors and lymphomas, as well as hematological malignancies. This is the first innovative biological drug approved by the FDA for clinical trials by GenSci, and shows that the technology and quality of GenSci's innovative R&D projects have reached the international standard.

See More
On December 18, 2020, Beijing time, GenSci’s Gentulizumab R&D project was approved by the US FDA for clinical trials, which means that this innovative therapy will soon proceed to clinical research in the United States. This is another milestone achievement following the approval of the project by the National Medical Products Administration (NMPA) for clinical trials in September of the same year.

The Gentulizumab injection is developed for advanced malignant solid tumors and lymphomas, as well as hematological malignancies. This is the first innovative biological drug approved by the FDA for clinical trials by GenSci, and shows that the technology and quality of GenSci's innovative R&D projects have reached the international standard.

Prev
1
Messages

CONTACT US

QUICK NAVIGATION

Copyright: Changchun GeneScience Pharmaceutical Co., Ltd.   吉ICP备14004136号

Copyright: Changchun GeneScience Pharmaceutical Co., Ltd.

吉ICP备14004136号